Vyzulta’s “Space Race”: A New Drug for the Reduction of Intraocular Pressure

Share on email
Share on print
Share on whatsapp

Glaucoma is a prominent cause of irreversible blindness, with a global prevalence of 3.45% among individuals between 40-80 years of age. The disease pathophysiology is multifactorial, but intraocular pressure (IOP) remains the singular modifiable risk factor . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading